



Q2 2021 results

28 July 2021

Cautionary statement regarding forward-looking statements



This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for FY 2020 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our second quarter 2021 earnings release and Annual Report on Form 20-F for FY 2020.

All expectations and targets regarding future performance and the dividend should be read together with the section "Outlook, assumptions and cautionary statements" on pages 68 and 69 of our second quarter 2021 earnings release.

Agenda



Q2 2021 progress

Emma Walmsley

Growth drivers

Luke Miels
Deborah Waterhouse
Dr. Hal Barron
Brian McNamara

Q2 2021 financial results

Iain Mackay

Q&A

Roger Connor
David Redfern



Q2 2021 progress

Emma Walmsley

**Q2 2021:
Strong
financial
performance
and execution
of strategic
priorities**

Strong Q2 financial performance: Sales +15%; Adjusted EPS +71% CER

Double-digit growth in New and Specialty Pharma and Vaccines

Good growth in Consumer Healthcare

Confident in delivering FY 2021 Adjusted EPS guidance

R&D delivers LA Cab PrEP filing and positive headline daprodustat results

BD strengthens pipeline in HIV, immuno-oncology, immuno-neurology[^]

Focused on delivering new growth outlooks and maximising value to shareholders

Progress made across all strategic priorities in Q2



Innovation

Positive Ph2/3 data:
daprodustat
COVID vaccines

Approvals/opinions:
Benlysta LN and
sotrovimab

Submissions:
Rolling NDA for
LA cabotegravir PrEP

ViiV/Halozyme:
ultra long-acting HIV
medicines

GSK/iTeos:
EOS-448 anti-TIGIT

GSK/Alector[^]:
AL001 & AL101
neurodegeneration

Performance

New and Specialty
Pharma products
+25% Q2, +14% H1

Lead indicators
position Shingrix for
recovery in US

6 of 9 CH power
brands growing
double-digit

Trust

MSCI
AA rating

Principal Partner
COP26

>1bn toothpaste
tubes recyclable by
2025

Priority is to unlock potential and maximise value for shareholders



¹ All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. 2021-26 CAGR is for the 5 years to 2026, using 2021 as the base year *Sales including Brands divested / under review, £9.5bn Continuing sales; **CER Proforma excluding brands divested/under review; ^Consumer Healthcare operating margin; ^^Therapeutic Oral Health, Pain Relief, Respiratory, Vitamins, Minerals, and Supplements and Digestive Health. All expectations and targets regarding future performance should be read together with the "Outlook, assumptions and cautionary statements" sections of the Second Quarter 2021 Results Announcement and the cautionary statement slide included with this presentation



Growth drivers

Luke Miels

Deborah Waterhouse


Dr. Hal Barron

Brian McNamara

Shingrix: strong underlying demand supports confidence in recovery



Volumes increasing as individuals complete COVID-19 vaccination series



- **US:** ~50% eligible patients expect to receive Shingrix within 1-3 months following COVID series completion³
 - Nearly 80% of adults 50+ now fully vaccinated for COVID²
 - NBRx volume +73% from start of Q2 2021 to end of quarter¹
 - Implementing strong, multi-channel DTC; maximising retailer engagement
- **Germany:** scripts improving as adults complete COVID series

US recovery on track for H2 2021



- **Q2 2021: Global sales** £295m +1% CER vs Q2 2020, reflecting challenging comparator period
 - US: TRx volume +77% vs Q2 2020
- **Unconstrained supply** to support US recovery and geographic expansion; availability expected in 16 countries by end 2021
- FDA approval received in 18+ immunocompromised population

Recent oncology launches contributing to growth




Zejula: US 1LM share grows despite COVID environment^{1,2}



- Q2 sales £98m, **+38% CER** despite 20% decrease in OC diagnosis²
 - Delayed surgeries impact new patient starts ~6 months after
 - Expect impact until OC diagnosis returns to pre-pandemic levels
- 59%² new patients going on a PARPi receive Zejula
- Watch-and-wait in 1LM decreased to 57%¹ with improved patient awareness
- Initiated Phase 3 study in ctDNA+ HER2- breast (ZEST); data 2025

Blenrep: demand shifting to earlier lines with US community oncologists³



Robust clinical program in place to optimize opportunity

3L/4L+: 36k patients ⁴	2L: 42k patients ⁴ Major Commercial Opportunity
DREAMM-3: mono vs. pom/dex; Pivotal data 1H22	DREAMM-7: combo w/ bor/dex, dose based on DREAMM-6; Pivotal Data 2H23
DREAMM-4: combo w/ pembro; Pilot data 1H22	DREAMM-8: combo w/ pom/dex, dose based on ALGONQUIN; Pivotal data 2H22
DREAMM-5: platform pilot trial; GSI combo data 2H21	1L: 67k patients⁴ Lower Probability of Success
	DREAMM-9: combo w/ bor/len/dex; Pilot data expected 2H22


1. Flatiron May 2021 2. IQVIA APLD (Data through May 2021)

3. IQVIA; Projected market sizing 4. Treatable Patients G7 (US, EU5, Japan), Kantar Health 2021 projected accessed 2019

HIV: Delivering sustainable growth



Dovato switch* continues to grow strongly



- Q2 sales (+14%) more than offsetting Q1 decline
- Half year growth of +1% across HIV portfolio
- Commercial execution driving performance in Dovato
- Early positive launch signals for Cabenuva
- Cabotegravir PrEP filing with FDA completed

* Source: IQVIA (R4W) and ActOne (R3M)

Compelling data presented at IAS Congress

Dovato:

- 48 week data for **SALSA** study demonstrate comparable efficacy and safety vs broad range of 3DRs, reinforcing Dovato use in a switch setting
- 48 week data for **STAT** study demonstrate applicability of Dovato as a first-line regimen in a rapid Test and Treat model of care

Cabenuva:

- 1 year data for **CUSTOMIZE** study identifies how to integrate Cabenuva into US healthcare practices; revealed patient preference over daily oral

Cabotegravir for prevention (PrEP):

- Virology and efficacy results from **HPTN 084** suggest predicted efficacy over one year follow-up of 91% for CAB-LA vs 15% for daily oral FTC/TDF

daprodustat: potential to be best in class for anaemia of chronic kidney disease



ascend/ND
NON-DIALYSIS

ascend/D
DIALYSIS

ascend/ID
INCIDENT DIALYSIS

ascend/TD
THREE-TIMES WEEKLY
DOSING IN DIALYSIS

ascend/NHQ
NON-DIALYSIS, HEMOGLOBIN
& QUALITY OF LIFE

- Five phase III studies
- >8,000 patients treated for up to 3.75 years
- Dialysis/ non-dialysis and incident dialysis patients
- Trial design aligned with global regulators
- Single haemoglobin target
- No meta-analysis required

All five studies met primary efficacy endpoint

Non-inferior vs erythropoietin in risk of MACE in both dialysis and non-dialysis

Full data to be presented at a forthcoming medical meeting

MACE: Major Adverse Cardiovascular Events

ASCEND ND and ASCEND D co-primary endpoints: Safety: MACE: All cause mortality, non-fatal MI, and non-fatal stroke; Efficacy mean change in haemoglobin from baseline
For trial summaries see: <https://www.gsk.com/media/7048/clinical-trials-summary.pdf>

Three significant business development transactions in Q2



Two clinical stage potential first-in-class mAbs for neurodegenerative diseases*

Progranulin elevating mAbs: AL001, and AL101

Progranulin is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative diseases

AL001: FTD-GRN phase III recruiting

- Updated Phase 2 data to be presented AAIC, 29 July

AL101: (Phase 1) for development in more prevalent neurodegenerative diseases (PD, AD)



anti-TIGIT enabling novel next-generation IO combinations

EOS448/GSK '859 Phase 1 dose escalation and anti-PD1 combination studies ongoing

Complements existing IO portfolio targeting the CD226 axis:

- CD96: GSK'608 (collaboration with 23andMe); Phase 1 ongoing
- anti-PVRIG: GSK'562 FTIH 2022



ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV

Exclusive license for four HIV medicine targets

- Potential in PrEP to increase cabotegravir dosing interval from every two months to up to six months

R&D focus on science of the immune system, human genetics and advanced technologies

* Pending Hart-Scott Rodino (HSR) clearance

FTD-GRN: frontotemporal dementia related to a mutation in the progranulin gene; PD, Parkinson's disease; AD, Alzheimer's disease; IO, immuno-oncology; PrEP, pre-exposure prophylaxis

AAIC: Alzheimer's Association International Conference, 26-30 July, Denver

FTIH: First time in Human

Significant upcoming R&D data points in next 18 months



H2 2021 data readouts: Specialty	
daprodustat Anaemia of CKD	ASCEND Phase 3
Blenrep r/r multiple myeloma	GSI combination cohort

H2 2021 data readouts: COVID solutions	
Medicago Vaccine	Phase 3
Sanofi (vidprevlyn) Vaccine	Phase 3
otilimab MAb therapeutic	OSCAR Phase 2 extension
sotrovimab MAb therapeutic	Phase 2 COMET-PEAK (IM)

Select pivotal data in 2022: Specialty and Vaccines	
Blenrep: DREAMM-3 3L multiple myeloma	H1 2022
Blenrep: DREAMM-8 2L multiple myeloma	H2 2022
otilimab: contRAst Rheumatoid arthritis	H2 2022
MenABCWY vaccine Meningococcal disease	H2 2022
RSV older adults RSV prophylaxis	H2 2022
RSV maternal RSV prophylaxis	H2 2022

CKD: Chronic Kidney Disease; GSI: Gamma Secretase Inhibitor; Mab, monoclonal antibody; 1L: First line treatment, 2L second line, 3L third line. r/r: relapsed/refractory

Consumer Healthcare

Q2 Revenue +7%¹, strong underlying category performance



Q2 Performance

- Continuing sales¹ Q2 +7% vs flat Q2 20²:
 - 2% drag from systems cutover benefit in Q2 prior year
 - strong performance in most categories
- Q2 2 year CAGR³ +3% and up +4% excluding seasonal cold flu and nasal products
- Ecommerce⁴ 7% sales up c.30%
- 6 of the 9 power brands gained or held share, with 6 power brands reporting double digit growth
- Emerging markets continuing sales increased double digit
- FY21 sales outlook unchanged

¹ CER sales excluding brands divested/under review

² CER Pro-forma sales excluding brands divested/under review

³ 2 year CAGRS calculated using 2020 CER Pro-forma sales excluding brands divested/under review

⁴ YTD May

	Growth CER (%)	
	Q2 ² 2020	Q2 ¹ 2021
Oral health	(1)	12
Pain relief	(2)	13
Vitamins, Minerals and supplements	19	(6)
Respiratory health	(11)	6
Digestive health & other	(4)	3
Continuing sales	0	7

Continuing sales 2 year CAGR³ 3

Consumer Healthcare

On track to create leading global consumer healthcare company



Key Milestones

- Divestment program completed in Q1 21 – with sales from brands divested under review in Q2 £33m (vs £116m Q2 20) and H1 £84m (vs £380m H1 20)
- Integration: On track
 - Commercial now fully complete
 - 3 major manufacturing sites (Guayama, Aprilia & Suzhou) transitioned to GSK systems, remaining site transitions on track
- 2022 guidance¹ retained:
 - £500m annual synergies
 - Mid to high 20s percent adjusted operating margin²

¹ As shared 19 December 2018 in the press release announcing the GSK and Pfizer Joint Venture

² At 2017 constant exchange rates



Q2 2021 results

Iain Mackay

Headline results



	Q2 2021	Reported %		H1 2021	Reported %	
	£m	AER	CER	£m	AER	CER
Turnover	8,092	6	15	15,510	(7)	(1)
Total operating profit	1,675	(41)	(30)	3,368	(31)	(21)
Total EPS	27.9p	(39)	(28)	49.4p	(36)	(27)
Adjusted operating profit	2,158	23	43	4,039	(9)	3
Adjusted EPS	28.1p	46	71	51.0p	(10)	2
Free cash flow	316	(84)	n/a	313	(87)	n/a

Results reconciliation

Q2 2021



	Total results	Intangible amortisation	Intangible impairment	Major restructuring	Transaction related	Disposals, significant legal and other	Separation costs	Adjusted results
Turnover (£bn)	8.1							8.1
Operating profit (£bn)	1.7	0.2	< 0.1	0.1	0.1	(0.1)	0.1	2.2
EPS (pence)	27.9	3.2	0.1	2.1	0.5	(6.9)	1.2	28.1
Q2 20 EPS (pence)	45.5	3.2	1.9	2.9	4.1	(38.7)	0.3	19.2


Group sales and adjusted operating margins

Q2 2021




Sales

All figures £m



Charts may not sum due to rounding

Adjusted operating margin




Adjusted operating profit to net income

Continued delivery of financial efficiency



	2Q20	2Q21
	£m	£m
Operating profit	1,749	2,158
Net finance expense	(227)	(185)
Share of associates	19	16
Tax	(316)	(366)
Tax rate	20.5%	18.4%
Non-controlling interests	(267)	(216)
Net income	958	1,407

Free cashflow of £0.3bn



CCL: contingent consideration liability

RAR: Returns and rebates

* Net Capex includes purchases less disposals of property, plant and equipment and intangibles

** Net operating cash is net cash inflow from operating activities including changes in working capital, excluding restructuring, operating CCL, and significant legal payments

*** Other includes significant legal payments, net interest paid, income from associates and JVs and distributions to minorities

Pharmaceuticals

Q2 2021




Sales

All figures £m

Q2 2021 Total : £4,229m: +12% CER; +3% AER



Operating profit & margin



Sales factors

- ⊕ New and Specialty growth
- ⊕ Favourable comparator due to destocking in Q2 2020
- ⊕ Favourable US return and rebate adjustments

Operating profit factors

- ⊕ Operating leverage from higher sales
- ⊕ Continued cost control
- ⊖ R&D investment

Vaccines


Q2 2021




Sales

All figures £m

Q2 2021 Total : £1,571m: +49% CER; +39% AER



Operating profit & margin



Sales factors

- ⊕ Pandemic adjuvant sales
- ⊕ Paediatric and adolescent demand
- ⊖ COVID-19 vaccination programme impact on routine adult vaccination

Operating profit factors

- ⊕ Operating leverage from higher sales
- ⊕ Positive mix due to pandemic adjuvant
- ⊖ R&D investment behind RSV and Meningitis programmes

Consumer Healthcare


Q2 2021




Sales

All figures £m

Q2 2021 Total : £2,292m: +3% CER; -4% AER



Operating profit & margin



Sales factors

- ⊕ Continued innovation benefit
- ⊕ Favourable comparator due to Q1 2020 accelerated purchase unwind
- ⊖ Impact of divested brands
- ⊖ 2 percentage point benefit in Q2 2020 from systems cutover

Operating profit factors

- ⊕ Synergy delivery and cost control
- ⊕ Price and volume growth
- ⊖ Impact of divested brands
- ⊖ A&P and manufacturing investment

2021 outlook

Confident in delivering FY guidance



Group H1 performance

Sales £15,510m, -1% CER
Adj OP £4,039m, +3% CER
Adj EPS 51.0p, +2% CER, including +7% contribution from COVID-19 solutions

Group Q3 considerations

Unfavourable year-on-year comparators in R&D and SG&A due to Q3 2020 one-time benefits

Group Q4 considerations

Adj EPS growth in H2 to be weighted to Q4

FY guidance: Adj EPS to decline mid-to-high single-digit percentage at CER (excl. COVID-19 solutions)

COVID-19 solutions: £276m sales

COVID-19 solutions:
Pursuing further contracting for pandemic adjuvant and sotrovimab

COVID-19 solutions expected to contribute approximately between 4% to 6% of Adj EPS growth at CER

* All expectations and targets regarding future performance should be read together with the "Outlook, assumptions and cautionary statements" sections of the Second Quarter 2021 Results Announcement and the cautionary statement slide included with this presentation; all figures at constant exchange rates (CER). Adj = Adjusted



Q&A session



Appendix



Adj EPS/Dividend

Adj EPS guidance:

Mid to high-single digit decline at CER, excluding COVID-19 solutions
COVID-19 solutions expected to contribute approximately 4% to 6% to growth at CER

Dividend:

Expect 80p for 2021

Pharmaceuticals

Turnover:

Flat to low-single digit growth for total Pharma, excluding divestments and COVID-19 solutions
High-single digit decline for Established Pharma

Adj operating costs

Adj SG&A and R&D:

Tight cost control, with targeted investments, and restructuring benefits
R&D investment to grow around 10% in 2021

Vaccines

Turnover:

Broadly flat, excluding pandemic adjuvant sales
Strong H2 global Shingrix performance expected with potential for slight full year growth
Flu global volumes to be broadly similar, without RAR benefit seen in 2020
Meningitis broadly flat, with pandemic impact
Established Vaccines to experience similar pressures as in 2020, largely informed by pandemic dynamics

Other Adj financials

Royalties:

Between £300-350m

Net finance expense:

Between £800-850m

Effective Tax rate:

Around 18%, excluding possible US tax reform

Consumer Healthcare

Turnover:

Low to mid-single digit growth for Consumer excluding brands divested/under review; outperforming the market
Sales of brands divested/under review to be around £150m

Across the Group, our turnover comments assume that healthcare systems and consumer trends approach normality in the second half of 2021; all turnover and growth comments at CER; Adj = Adjusted

All expectations and targets regarding future performance should be read together with the "Outlook, assumptions and cautionary statements" sections of the Second Quarter 2021 Results Announcement and the cautionary statement slide included with this presentation

Expected costs and savings under Major Restructuring Programmes & Consumer Separation



	Date Announced	£bn 2021 Average Rates	Cumulative Actuals to 2020	H1 2021 Actuals	2021	2022	2023	Total Lifetime
					Projected ¹			
2018 Restructuring Programme (Incl. Tesaro)	Q2'18	Savings ²	0.3	0.4	0.5			0.5
		Total charges	1.5	-	0.1			1.6
		Cash payments	0.3	0.1	0.2	-		0.5
Consumer JV	Dec-18	Synergies ²	0.3	-	0.4	0.5		0.5
		Total charges	0.6	-	0.2	-		0.8
		Cash payments	0.5	0.1	0.1	0.1		0.7
Separation Preparation Programme	Feb-20	Savings ²	0.1	-	0.4	0.8	1.0	1.0
		Total charges	0.8	0.2	1.1	0.5	-	2.4
		Cash payments	0.2	0.2	0.6	0.7	0.1	1.6
Separation Costs³		Total charges	0.1	0.1	0.3	0.2	-	0.6
		Cash payments	0.1	0.1	0.3	0.2	-	0.6

¹ All expectations and targets regarding future performance should be read together with the "Outlook assumptions and cautionary statement" sections of the Second Quarter 2021 Results Announcement and the cautionary statement slide included with this presentation

² Savings and synergies shown are cumulative for the programme to date throughout the table

³ Excludes Capex

Our R&D pipeline

63 potential vaccines and medicines



Phase I

C. difficile* vaccine
Klebsiella pneumoniae* vaccine
MenABCWY (2 nd gen) vaccine
SAM (COVID-19 model) vaccine
SAM (rabies model) vaccine
BVL-GSK098* (ethionamide booster) tuberculosis
VIR-2482* (neutralizing monoclonal antibody) influenza
2556286* (Mtb inhibitor) tuberculosis
3186899** (CRK-12 inhibitor) visceral leishmaniasis
3494245* (proteasome inh) visceral leishmaniasis
3882347* (FimH antagonist) uUTI
3923868 (PI4kβ inhibitor) viral COPD exacerbations
4182137* (VIR-7832) COVID-19†
3739937 (maturation inhibitor) HIV
teladilimab* (3359609, ICOS agonist) multiple myeloma
3326595* (PRMT5 inhibitor) cancer
3368715* (Type 1 PRMT inhibitor) cancer
3745417 (STING agonist) cancer
3845097* (NY-ESO-1/TGFβR2 TCR T) cancer
3901961* (NY-ESO-1/CD8a TCR T) cancer
4074386* (TSR-033, LAG3 antagonist) cancer
4362676* (Mat2A inhibitor) cancer
4428859** (EOS-448, TIGIT antagonist) cancer
6097608* (CD36 antagonist) cancer
AL101** (anti-sortilin) neurodegenerative disorders
2982772 (RIP1-k) psoriasis
3858279* (CCL17 inhibitor) osteoarthritis pain
3915393* (TG2 inhibitor) celiac disease
2798745* (TRPV4 blocker) diabetic macular edema

Phase II

COVID-19 (SK Bioscience)**† vaccine
Malaria (fractional dose)* vaccine
S. aureus**† vaccine
Shigella* vaccine
Therapeutic HBV**† vaccine
bepirovirsen* (3228836, HBV ASO) HBV
3036656* (leucyl t-RNA inhibitor) tuberculosis
3640254 (maturation inhibitor) HIV
3810109* (broadly neutralizing antibody) HIV
bintrafusp alfa* (TGFβ trap/anti-PDL1) biliary tract cancer**
cobolimab* (TSR-022, TIM-3 antagonist) NSCLC
lincixibat (IBATI) cholestatic pruritus in primary biliary cholangitis

Phase III/Registration

Bexsero infants (US) vaccine
COVID-19 (Medicago)**† vaccine
COVID-19 (Sanofi)**† vaccine
MenABCWY (1 st gen) vaccine
Menveo liquid ³ vaccine
MMR (US) vaccine
Rotarix liquid (US) vaccine
RSV maternal* vaccine
RSV older adults* vaccine
gepotidacin* (2140944) uUTI and GC
sotrovimab* (VIR-7831) COVID-19
cabotegravir LA HIV PrEP
Blenrep* (anti-BCMA ADC) multiple myeloma
Jemperli* (PD-1 antagonist) solid tumours**
letetresgene-autoleuce1 ³ (3377794, NY-ESO-1 TCR) SS/MRCLS**
Zejula* (PARP inhibitor) ovarian & lung cancer**
AL001** (anti-sortilin) frontotemporal dementia ⁵
Benlysta + Rituxan systemic lupus erythematosus
depemokimab* (LA anti-IL5 antagonist) asthma
Nucala COPD / nasal polyps
otilimab* (3196165, aGM-CSF inhibitor) rheumatoid arthritis**
daprodustat (HIF-PHI) anaemia in chronic kidney disease

- Infectious Diseases
- HIV (ViiV)
- Oncology
- Immunology/Respiratory
- Opportunity Driven

Note: Only the most advanced indications are shown for each asset

*In-license or other alliance relationship with third party (Jemperli, cobolimab and LAG-3 are Tesaro assets); **Additional indications also under investigation; † GSK contributing pandemic adjuvant
 1. In Phase 1/2 study 2. Transition activities underway to enable further progression by partner 3. In potentially registrational Ph2 trial 4. Pending Hart-Scott Rodino (HSR) clearance 5. Ph3 trial in patients with progranulin gene mutation
 NSCLC: non-small cell lung cancer; uUTI: uncomplicated urinary tract infection; GC: gonorrhea; SS: synovial sarcoma ; MRCLS: myxoid/round cell liposarcoma; PrEP: pre-exposure prophylaxis

Our R&D pipeline

Upcoming late-stage milestones that will inform our progress



	2H 2021	2022
Regulatory decisions	Shingrix immuno-compromised Jemperli [^] – dMMR/MSI-H solid tumors Nucala – nasal polyposis	cabotegravir – HIV PrEP; 1H 2022 MMR vaccine (US); mid 2022
Regulatory submissions		Blenrep DREAMM-3 – 3L+ multiple myeloma; 2H 2022 daprodustat ASCEND – anaemia in chronic kidney disease; 1H 2022 Jemperli RUBY ^{2^} – 1L endometrial cancer; 2H 2022 Rotarix (liquid US) – 1H 2022
Late-stage readouts	<u>Phase 3:</u> daprodustat ASCEND – anaemia in chronic kidney disease COVID-19 (Medicago) vaccine COVID-19 (Sanofi) vaccine <u>Phase 2</u> otilimab OSCAR ¹ – severe COVID-19 related pulmonary disease sotrovimab COMET-PEAK – COVID-19 (IM)	<u>Phase 3:</u> sotrovimab COMET-TAIL – COVID-19 (IM); 1H 2022 gepotidacin EAGLE ² – uUTI; 1H 2022 Blenrep DREAMM-3 – 3L+ MM; 1H 2022 Blenrep DREAMM-8 – 2L+ MM; 2H 2022 Jemperli RUBY ^{2^} – 1L endometrial cancer; mid 2022 otilimab contRAst – rheumatoid arthritis; 2H 2022 MenABCWY vaccine; 2H 2022 RSV older adults vaccine; 2H 2022 RSV maternal vaccine; 2H 2022 <u>Phase 2</u> bepirovirsen (HBV ASO) BE-CLEAR ³ – HBV; 1H 2022

1. Potentially registrational Ph2 trial
 2. Interim analysis
 3. Ph2b data

Late-stage defined as Phase 2b onwards IM: Intramuscular ^ Tesaro asset

Our R&D pipeline

Changes in the portfolio since Q1 2021



New to Phase I	New to Phase II	New to Phase III	New to Registration
<p>VIR-2482¹ (neutralizing monoclonal antibody) influenza</p> <p>AL101² (anti-sortilin monoclonal antibody) neurodegenerative disorders</p> <p>GSK'859 (EOS-448, TIGIT antagonist) cancer</p> <p>Klebsiella pneumoniae vaccine</p> <p>MenABCWY (2nd gen) vaccine</p>	<p>GSK'109 (broadly neutralizing antibody) HIV</p> <p>S. Aureus vaccine</p>	<p>AL001² (anti-sortilin monoclonal antibody) FTD-GRN: frontotemporal dementia related to a mutation in the progranulin gene</p> <p>COVID-19 (Sanofi) vaccine</p> <p>Menveo liquid vaccine</p>	<p>MMR (US) vaccine</p>
Removed from Phase I	Removed from Phase II	Removed from Phase III	Removed from Registration
	<p>RSV paediatric vaccine</p> <p>feladilimab (3359609, ICOS agonist) solid tumors³</p>		<p>Shingrix immuno-compromised (FDA approval)</p>

1. Added to GSK pipeline as part of extended VIR collaboration with option for co-development after Ph2 completion
2. AL101 and AL001 pending HSR clearance
3. In Ph1 for combination with Blenrep in platform trial DREAMM-5